MX361779B - Estabilidad mejorada de soluciones de clorhidrato de hidromorfona. - Google Patents

Estabilidad mejorada de soluciones de clorhidrato de hidromorfona.

Info

Publication number
MX361779B
MX361779B MX2014010622A MX2014010622A MX361779B MX 361779 B MX361779 B MX 361779B MX 2014010622 A MX2014010622 A MX 2014010622A MX 2014010622 A MX2014010622 A MX 2014010622A MX 361779 B MX361779 B MX 361779B
Authority
MX
Mexico
Prior art keywords
hydromorphone hydrochloride
improved stability
hydrochloride solutions
solutions
hydromorphone
Prior art date
Application number
MX2014010622A
Other languages
English (en)
Other versions
MX2014010622A (es
Inventor
J Foster John
R Prentice Thomas
Original Assignee
Piramal Critical Care Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Piramal Critical Care Ltd filed Critical Piramal Critical Care Ltd
Publication of MX2014010622A publication Critical patent/MX2014010622A/es
Publication of MX361779B publication Critical patent/MX361779B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

En general, la presente invención se relaciona con una solución estéril de clorhidrato de hidromorfona que está sustancialmente libre de un amortiguador.
MX2014010622A 2012-03-07 2013-03-06 Estabilidad mejorada de soluciones de clorhidrato de hidromorfona. MX361779B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261607774P 2012-03-07 2012-03-07
PCT/US2013/029328 WO2013134362A1 (en) 2012-03-07 2013-03-06 Improved stability of hydromorphone hydrochloride solutions

Publications (2)

Publication Number Publication Date
MX2014010622A MX2014010622A (es) 2014-11-14
MX361779B true MX361779B (es) 2018-12-17

Family

ID=48045027

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014010622A MX361779B (es) 2012-03-07 2013-03-06 Estabilidad mejorada de soluciones de clorhidrato de hidromorfona.

Country Status (8)

Country Link
EP (1) EP2822535A1 (es)
JP (1) JP6074442B2 (es)
KR (1) KR101710244B1 (es)
CN (1) CN104244925B (es)
CA (1) CA2865815C (es)
IL (1) IL234452B (es)
MX (1) MX361779B (es)
WO (1) WO2013134362A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9155734B2 (en) 2012-03-07 2015-10-13 Mallinckrodt Llc Stability of hydromorphone hydrochloride solutions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7244696A (en) * 1995-09-29 1997-04-17 Lam Pharmaceuticals Inc. Sustained release delivery system and long acting narcotic analgesics and antagonists
US20040102476A1 (en) * 2002-11-25 2004-05-27 Chan Tai Wah High concentration formulations of opioids and opioid derivatives
CN102333443A (zh) 2009-02-26 2012-01-25 帝国制药美国公司 治疗癌症疼痛的麻醉乳液制剂
WO2011019954A2 (en) * 2009-08-13 2011-02-17 Yehuda Ivri Intracochlear drug delivery to the central nervous system
ES2444591T3 (es) 2010-10-28 2014-02-25 Acino Pharma Ag Medicamento con el principio activo hidromorfona con estabilidad al almacenamiento mejorada

Also Published As

Publication number Publication date
EP2822535A1 (en) 2015-01-14
JP6074442B2 (ja) 2017-02-01
WO2013134362A1 (en) 2013-09-12
JP2015509541A (ja) 2015-03-30
CN104244925B (zh) 2017-03-29
KR101710244B1 (ko) 2017-02-24
IL234452B (en) 2020-01-30
CA2865815C (en) 2017-06-13
KR20140132765A (ko) 2014-11-18
MX2014010622A (es) 2014-11-14
CA2865815A1 (en) 2013-09-12
CN104244925A (zh) 2014-12-24

Similar Documents

Publication Publication Date Title
PH12015501083A1 (en) Novel pyridine derivatives
PH12015501843A1 (en) Novel pyrazol derivatives
IN2015DN00598A (es)
MY182328A (en) Pyridine-2-amides useful as cb2 agonists
JO3241B1 (ar) عملية لتحضير محلول مائي يتألف على الاقل من كربونات هيدروجين الكيل خبأ واستخدامه
MX370649B (es) Proceso para la preparacion de teneligliptina.
CR20150084A (es) 2-oxo-2,3-dihidro-indoles
PH12015502032A1 (en) Azetidinyloxyphenylpyrrolidine compounds
IN2014DN06192A (es)
IN2013MU03070A (es)
IN2013MU01113A (es)
MX2014008918A (es) Nuevos derivados de pirrolidina.
MX363458B (es) Nuevos derivados de tetrazolona.
IN2014DN09451A (es)
MX2014009084A (es) Derivados de pirimidooxazocina como inhibidores de mtor.
IN2013MU04056A (es)
MX361779B (es) Estabilidad mejorada de soluciones de clorhidrato de hidromorfona.
MX2015011881A (es) Proceso para la preparacion de 3,7-dimetilnonan-1-ol.
MY168058A (en) Optical transducer with integrated feedthrough
MX351093B (es) Nuevos derivados de azetidina.
IN2014DN07498A (es)
UA106105C2 (uk) Застосування похідних 2-оксоіндолін-3-гліоксилової кислоти як засобів з антидепресивною дією
IN2013CH04519A (es)
IN2013CH05395A (es)
UA65080U (ru) Применение полиорганосилсесквиоксана в качестве отвердителя эпоксидных смол

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: PIRAMAL CRITICAL CARE LIMITED

FG Grant or registration